Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800589 | 0.91 | NAMPT (0.42) | NAMPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6795268 | 0.89 | NPC1 (0.38) | NAMPTSMN1; SMN2KMT2ADRD3 | |
| Trifluoroacetic Acid SCHEMBL6800303 | 0.88 | HTR1A (0.40) | NAMPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6791640 | 0.88 | ALDH1A1 (0.43) | NAMPTSMN1; SMN2CYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL6791548 | 0.86 | CYP1A2 (0.33) | NAMPTCYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL1655698 | 0.86 | CYP1A2 (0.30) | CYP1A2CYP3A4CYP2C9HPGDCYP2C19 | |
| SCHEMBL4262730 | 0.86 | DPP7 (0.34) | SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL6794266 | 0.86 | KMT2A (0.41) | SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL6791910 | 0.86 | ROCK2 (0.38) | NAMPTCYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL6792951 | 0.84 | CYP1A2 (0.37) | NAMPTCYP1A2CYP3A4CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | NAMPT 658/4885SMN1; SMN2 4333/4885CYP1A2 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.